Hank Nordhoff currently serves as Chairman and CEO of Banyan Biomarkers. Previously, he served as President and CEO of Gen-Probe Inc. for fifteen years until his retirement in May 2009. In December 2011, he retired as Chairman of the Board. Prior to joining Gen-Probe Inc., Mr. Nordhoff served as President and CEO of TargeTech, Inc., a gene therapy company focused on the treatment of inherited diseases, which was merged into the Immune Response Corporation in 1992. Previously, Mr. Nordhoff spent over 16 years at Pfizer Inc. where he held several senior positions in Brussels, Seoul, Tokyo and New York.
He currently serves as Chairman of Chugai Pharmaceutical USA and is a board member of Mannkind Corporation. In the non profit world, he is a board member of 9 organizations including The Prostate Cancer Foundation, the Moores Cancer Center of UCSD, The Jacobs School of Engineering of UCSD, The Rady Childrens Hospital, and The Sanford Burnham Medical Research Institute. He is past Chair of the San Regional Economic Development Corporation and past Chair of the California Healthcare Institute and a former member of the Delta Stewardship Council.
Mr. Nordhoff received his Bachelor of Arts degree in International Relations and Political Economy from Johns Hopkins University and earned a Master's degree in International Business and Finance from Columbia University.